New hope for advanced cancer patients as First-in-Human drug trial begins
NCT ID NCT07265921
Summary
This is the first time a new drug called SIM0609 is being tested in people. The main goals are to find a safe dose and see how the body processes it. The study will also look for early signs that the drug might help shrink tumors in adults with advanced solid cancers who have no other standard treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hubei Cancer Hospital
NOT_YET_RECRUITINGWuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Cancer Hospital
NOT_YET_RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongshan Hospital，Fudan University
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.